Allergy Therapeutics trading ahead of expectations

Allergy Therapeutics specialises in the research and development of treatments and vaccines for allergies such as hay fever.

The company is well-established in Europe with a pipeline of products also in clinical development for grass, tree and house dust mites and a peanut allergy vaccine in pre-clinical stages.

() has hailed the results from a study that it said demonstrated a “clear treatment effect” from its short-course immunotherapy targeting grass pollen allergies.

The exploratory field trial was designed to evaluate the efficacy and safety of Grass MATA MPL.

The primary aim was achieved with the jab providing a “clinically relevant improvement” across both active treatment groups compared to placebo with no medicinal value.

Specifically, there was a 29.1% improvement in the symptoms for those on the six-week course, which rose to 36.8% for those receiving treatment over 14 weeks. Quality of life was also enhanced, the data showed. The drug was well tolerated.

Allergy Therapeutics PLC (AIM:AGY, FRA:HHU) said it has enough cash to fund the current clinical trials of its grass allergy and peanut allergy vaccines with just a small amount of debt.

The next milestones for investors to look forward to include results from the Grass MATA MPL G309 exploratory field trial in the autumn, the pre-application meeting with the US Food and Drug Administration (FDA) for VLP Peanut, followed by the start in 2022 of the VLP Peanut Phase I PROTECT study in the US.

Allergy Therapeutics PLC (AIM:AGY, FRA:HHU) said ImmunoBON, its protein-based oral product for the treatment of allergies, was voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation Awards in Germany.

The awards, held every year, are based on the Pharma Trend benchmark study, which seeks the views of 700 physicians, 100 pharmacists and 600 patients in Germany.

Allergy Therapeutics PLC (AIM:AGY, FRA:HHU)’s study evaluating biomarkers from peanut-allergic patients’ blood samples using its VLP Peanut vaccine candidate confirm its hypoallergic potential and should strengthen the company’s Phase I study IND application to the FDA in late 2021, says finnCap.

While the broker’s target price remains 45p, it adds there is substantial potential upside as VLP Peanut progresses through the clinic.

() () Head of Business Innovation Alan Bullimore caught up with Proactive London to talk about the results from a study targeting grass pollen allergies.

The exploratory field trial was designed to evaluate the efficacy and safety of Grass MATA MPL.

As he explains there was a 29.1% improvement in the symptoms for those on the six-week course, which rose to 36.8% for those receiving treatment over 14 weeks.